Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn (ACCORDO)

A Randomised, Double-blind, Placebo-controlled Study to Evaluate if Rasagiline Can Improve Depressive Symptoms and Cognitive Function in Non-demented, Idiopathic Parkinson's Disease Patients: ACCORDO Study

The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total score.

Study Overview

• Status: Completed
• Conditions: Parkinson's Disease; Depressive Symptoms
• Intervention / Treatment: Drug: Rasagiline; Drug: Placebo

Detailed Description

ACCORDO is a multicentre, randomised, double-blind, and placebo-controlled study conducted in 12 Italian centres. Subjects are screened by means of the BDI-IA (cut-off 15) and randomised to treatment with rasagiline or placebo for 12 weeks.

Subjects have to be on stable treatment with dopaminergic agents at least 4 weeks before baseline, and maintained so during the course of the study.

The primary objective is to evaluate whether rasagiline compared to placebo improves depressive symptoms as evaluated by the BDI-IA total score.

• Study Type: Interventional
• Enrollment (Actual): 121
• Phase: Phase 4

Contacts and Locations

Study Locations

• Italy
  • Cagliari, Italy, 9134
    • IT010
  • Chieti, Italy, 66013
    • IT007
  • Genova, Italy, 16132
    • IT004
  • Lido di Camaiore, Italy, 55043
    • IT005
  • Messina, Italy, 98122
    • IT003
  • Milano, Italy, 20135
    • IT012
  • Naples, Italy, 80131
    • IT001
  • Roma, Italy, 161
    • IT011
  • Rome, Italy, 133
    • IT008
  • Torino, Italy, 10126
    • IT015
  • Venezia, Italy, 30126
    • IT013
  • Verona, Italy, 37134
    • IT009

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 40 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Outpatient, male or female aged >=40 and <80 years. The subject has a diagnosis of idiopathic Parkinson's Disease (PD) according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria for PD for the clinical diagnosis of PD.
• Depressive symptoms with a minimum severity of >=15 using the BDI-IA.
• Hoehn and Yahr stage I-III.
• Under stable (4 weeks prior to baseline) dopaminergic treatment without significant motor complication such as "on-off" phenomena and/or dyskinesia.
• The subject and/or legal representative and/or impartial witness is/are able to read and understand the Subject Information Sheet.
• The subject and/or legal representative has/have signed the Informed Consent Form (ICF) and if relevant the impartial witness has co-signed the ICF.
• If female, must: agree not to try to become pregnant during the study (female patients of childbearing potential will take pregnancy test, using a urine stick), AND use adequate contraception (adequate contraception is defined as oral/systemic contraception, intrauterine device, diaphragm in combination with spermicidal, or condom for male partner in combination with spermicidal), OR have been menopausal for at least 24 months prior to baseline, (OR) have been surgically sterilised prior to baseline, OR have had a hysterectomy prior to baseline.

Exclusion Criteria:

A subject, who meets one or more of the following criteria at the Baseline Visit, is not eligible for inclusion in this study:

• Motor complications such as wearing off and on-off phenomena.
• Mini-Mental State Examination (MMSE) <26, corrected score.
• Diagnosis of current or history of major depressive episode according to DSM-IV-TR® criteria within 1 year before recruitment into the study.
• Presence of any other neurodegenerative disorder other than PD, based on judgement of investigator.
• Psychotic symptoms, e.g. hallucination and delirium (determined by clinical evaluation).
• Presence of any unstable or untreated systemic disorder such as diabetes, cardiac failure, or renal failure.
• Use of any prohibited concomitant medication according to the timelines provided in Appendix II.
• Patient who have undergone Deep Brain Stimulation surgery.
• Current treatment with antidepressants or history of treatment with antidepressants less than 1 month prior to randomisation.
• Current treatment or history of treatment less than 1 month prior to randomisation, with antipsychotics, cholinesterase inhibitors, memantine, amantadine, or anticholinergics.
• Current treatment with selegiline or history of treatment with selegiline less than 90 days prior to randomisation.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: Placebo	Drug: Placebo; Once daily for 12 weeks; orally
Experimental: Rasagiline	Drug: Rasagiline; 1 mg/day for 12 weeks; orally; Other Names: Azilect

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change from baseline in BDI-IA total score	12 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Evaluate if rasagiline compared to placebo improves cognitive function, over a treatment period of 12 weeks in idiopathic Parkinson´s Disease, using a formal neuropsychiatric cognitive test battery; quality of life (PDQ 39); apathy; ADL, motor function	12 weeks
Change in quality of life using the PDQ-39 scale	12 weeks
Change in apathy using the Apathy Scale	12 weeks
Change in ADL and motor function using UPDRS scales part II and III, respectively	12 weeks

Collaborators and Investigators

• Sponsor: Lundbeck Italia S.p.A.
• Collaborators: Teva Branded Pharmaceutical Products R&D, Inc.

Study record dates

Study Major Dates

• Study Start: March 1, 2010
• Primary Completion (Actual): July 1, 2012
• Study Completion (Actual): July 1, 2012

Study Registration Dates

• First Submitted: January 22, 2010
• First Submitted That Met QC Criteria: January 22, 2010
• First Posted (Estimate): January 25, 2010

Study Record Updates

• Last Update Posted (Actual): August 31, 2021
• Last Update Submitted That Met QC Criteria: August 30, 2021
• Last Verified: August 1, 2021

More Information

Terms related to this study

• Keywords: Cognition; Rasagiline; Depressive Symptoms
• Additional Relevant MeSH Terms: Behavioral Symptoms; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Depression; Parkinson Disease; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Neuroprotective Agents; Protective Agents; Monoamine Oxidase Inhibitors; Rasagiline
• Other Study ID Numbers: 12962A; 2009-011144-19 (EudraCT Number)

Plan for Individual participant data (IPD)

Study Data/Documents

1. EMA EudraCT Results
   Information identifier: 2009-011144-19

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No